Stock A290650 L&C BIO CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials L&C Bio Co., Ltd

Equities

A290650

KR7290650001

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 02/05/2024 BST 		5-day change 1st Jan Change
20,700 KRW -1.90% Intraday chart for L&C Bio Co., Ltd +5.34% -28.62%
03-27 Ray Co., Ltd. announced that it has received KRW 25 billion in funding from KB Securities Co., Ltd., L&C Bio Co., Ltd, Samsung Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., NH Investment & Securities Co., Ltd., Hanwha Investment & Securities Co., Ltd. CI
03-25 Ray Co., Ltd. announced that it expects to receive KRW 25 billion in funding from KB Securities Co., Ltd., L&C Bio Co., Ltd, Samsung Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., NH Investment & Securities Co., Ltd., Hanwha Investment & Securities Co., Ltd. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 142,155 188,399 754,757 830,267 524,021 657,862
Enterprise Value (EV) 1 106,571 161,278 742,445 817,478 593,649 680,803
P/E ratio 23.7 x 25.9 x 69.9 x 59.1 x 116 x 13.8 x
Yield - 0.39% 0.14% 0.14% 0.22% 0.34%
Capitalization / Revenue 6.69 x 6.46 x 22.9 x 18.2 x 9.97 x 9.55 x
EV / Revenue 5.02 x 5.53 x 22.5 x 17.9 x 11.3 x 9.89 x
EV / EBITDA 17.9 x 15.9 x 83.3 x 50.9 x 42.4 x 50.8 x
EV / FCF -42.9 x 161 x 427 x -92.9 x -11.9 x -27.8 x
FCF Yield -2.33% 0.62% 0.23% -1.08% -8.38% -3.59%
Price to Book 2.71 x 3.24 x 13.1 x 9.77 x 5.35 x 4.48 x
Nbr of stocks (in thousands) 21,703 22,078 21,877 22,685 22,685 22,685
Reference price 2 6,550 8,533 34,500 36,600 23,100 29,000
Announcement Date 15/03/19 18/03/20 22/03/21 21/03/22 21/03/23 20/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 21,241 29,152 32,973 45,677 52,572 68,870
EBITDA 1 5,959 10,118 8,911 16,072 13,992 13,402
EBIT 1 5,477 9,032 7,324 13,170 9,484 7,748
Operating Margin 25.79% 30.98% 22.21% 28.83% 18.04% 11.25%
Earnings before Tax (EBT) 1 5,891 9,922 12,944 17,095 4,563 62,938
Net income 1 5,208 7,250 10,813 13,814 4,544 48,361
Net margin 24.52% 24.87% 32.79% 30.24% 8.64% 70.22%
EPS 2 276.5 330.0 493.8 619.5 200.0 2,096
Free Cash Flow 1 -2,483 1,000 1,739 -8,801 -49,766 -24,469
FCF margin -11.69% 3.43% 5.28% -19.27% -94.66% -35.53%
FCF Conversion (EBITDA) - 9.89% 19.52% - - -
FCF Conversion (Net income) - 13.8% 16.09% - - -
Dividend per Share - 33.33 50.00 50.00 50.00 100.0
Announcement Date 15/03/19 18/03/20 22/03/21 21/03/22 21/03/23 20/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2023 Q2 2023 Q3
Net sales 1 11.94 13.47 11 13.14 16.49 20.56
EBITDA - - - - - -
EBIT 1 3.196 4.57 2.03 2.212 1.613 4.753
Operating Margin 26.76% 33.93% 18.45% 16.83% 9.78% 23.12%
Earnings before Tax (EBT) - - - - - -
Net income 1 - 9.204 1.262 1.138 1.37 49.8
Net margin - 68.34% 11.48% 8.66% 8.31% 242.22%
EPS - - - - - -
Dividend per Share - - - - - -
Announcement Date 11/11/21 17/02/22 13/05/22 12/08/22 14/08/23 14/11/23
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - 69,628 22,942
Net Cash position 1 35,584 27,121 12,311 12,789 - -
Leverage (Debt/EBITDA) - - - - 4.976 x 1.712 x
Free Cash Flow 1 -2,483 1,000 1,739 -8,801 -49,766 -24,469
ROE (net income / shareholders' equity) 14.6% 15% 20% 20.2% 5.66% 36.7%
ROA (Net income/ Total Assets) 8.79% 9.13% 6.24% 8.76% 3.86% 2.1%
Assets 1 59,229 79,372 173,387 157,740 117,728 2,306,750
Book Value Per Share 2 2,417 2,635 2,642 3,748 4,318 6,478
Cash Flow per Share 2 996.0 578.0 1,018 766.0 291.0 659.0
Capex 1 4,739 1,957 3,016 10,251 37,531 24,503
Capex / Sales 22.31% 6.71% 9.15% 22.44% 71.39% 35.58%
Announcement Date 15/03/19 18/03/20 22/03/21 21/03/22 21/03/23 20/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Medical Devices & Implants

1st Jan change Capi.
L&C BIO CO., LTD Stock L&C Bio Co., Ltd
-28.62% 347M
STRYKER CORPORATION Stock Stryker Corporation
+9.68% 125B
SMITH & NEPHEW PLC Stock Smith & Nephew Plc
-7.58% 10.91B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD. Stock Imeik Technology Development Co.,Ltd.
+2.17% 8.93B
INSPIRE MEDICAL SYSTEMS, INC. Stock Inspire Medical Systems, Inc.
+22.75% 7.57B
GLAUKOS CORPORATION Stock Glaukos Corporation
+33.99% 5.36B
AXONICS, INC. Stock Axonics, Inc.
+8.12% 3.43B
ENOVIS CORPORATION Stock Enovis Corporation
-8.48% 2.81B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD. Stock Beijing Balance Medical Technology Co.,Ltd.
-5.07% 2.23B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD. Stock Shanghai MicroPort Endovascular MedTech Co., Ltd.
-4.22% 2.13B
Medical Devices & Implants
  1. Stock Market
  2. Equities
  3. A290650 Stock
  4. Financials L&C Bio Co., Ltd